|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zagryazhskaya A, Gyuraszova K and
Zhivotovsky B: Cell death in cancer therapy of lung adenocarcinoma.
Int J Dev Biol. 59:119–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yatabe Y, Borczuk AC and Powell CA: Do all
lung adenocarcinomas follow a stepwise progression? Lung Cancer.
74:7–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang
XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, et al: EGFR
mutation heterogeneity and the mixed response to EGFR tyrosine
kinase inhibitors of lung adenocarcinomas. Oncologist. 17:978–985.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Devarakonda S, Morgensztern D and Govindan
R: Genomic alterations in lung adenocarcinoma. Lancet Oncol.
16:e342–e351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ben-Baruch A: The tumor-promoting flow of
cells into, within and out of the tumor site: Regulation by the
inflammatory axis of TNFα and chemokines. Cancer
Microenviron. 5:151–164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wajant H: The role of TNF in cancer.
Results Probl Cell Differ. 49:1–15. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zelová H and Hošek J: TNF-α
signalling and inflammation: Interactions between old
acquaintances. Inflamm Res. 62:641–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:3666–3670.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haranaka K, Satomi N and Sakurai A:
Antitumor activity of tumor necrosis factor (TNF) in vitro and in
vivo. Gan To Kagaku Ryoho. 11:1387–1393. 1984.(In Japanese).
PubMed/NCBI
|
|
12
|
Calzascia T, Pellegrini M, Hall H, Sabbagh
L, Ono N, Elford AR, Mak TW and Ohashi PS: TNF-alpha is critical
for antitumor but not antiviral T cell immunity in mice. J Clin
Invest. 117:3833–3845. 2007.PubMed/NCBI
|
|
13
|
Fajardo LF, Kwan HH, Kowalski J, Prionas
SD and Allison AC: Dual role of tumor necrosis factor-alpha in
angiogenesis. Am J Pathol. 140:539–544. 1992.PubMed/NCBI
|
|
14
|
Weishaupt A, Gold R, Hartung T, Gaupp S,
Wendel A, Brück W and Toyka KV: Role of TNF-alpha in high-dose
antigen therapy in experimental autoimmune neuritis: Inhibition of
TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and
prevents liver necrosis. J Neuropathol Exp Neurol. 59:368–376.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bertazza L and Mocellin S: The dual role
of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem.
17:3337–3352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Semenza GL and Wang GL: A nuclear factor
induced by hypoxia via de novo protein synthesis binds to the human
erythropoietin gene enhancer at a site required for transcriptional
activation. Mol Cell Biol. 12:5447–5454. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JW, Bae SH, Jeong JW, Kim SH and Kim
KW: Hypoxia-inducible factor (HIF-1)alpha: Its protein stability
and biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weidemann A and Johnson RS: Biology of
HIF-1alpha. Cell Death Differ. 15:621–627. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schindl M, Schoppmann SF, Samonigg H,
Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P
and Oberhuber G; Austrian Breast and Colorectal Cancer Study Group,
: Overexpression of hypoxia-inducible factor 1alpha is associated
with an unfavorable prognosis in lymph node-positive breast cancer.
Clin Cancer Res. 8:1831–1837. 2002.PubMed/NCBI
|
|
22
|
Chiavarina B, Whitaker-Menezes D, Migneco
G, Martinez-Outschoorn UE, Pavlides S, Howell A, Tanowitz HB,
Casimiro MC, Wang C, Pestell RG, et al: HIF1-alpha functions as a
tumor promoter in cancer associated fibroblasts, and as a tumor
suppressor in breast cancer cells: Autophagy drives
compartment-specific oncogenesis. Cell Cycle. 9:3534–3551. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan LF, Diao LM, Chen DJ, Liu MQ, Zhu LQ,
Li HG, Tang ZJ, Xia D, Liu X and Chen HL: Expression of HIF-1 alpha
and its relationship to apoptosis and proliferation in lung cancer.
Ai Zheng. 21:254–258. 2002.(In Chinese). PubMed/NCBI
|
|
24
|
Balamurugan K: HIF-1 at the crossroads of
hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haffner C, Jarchau T, Reinhard M, Hoppe J,
Lohmann SM and Walter U: Molecular cloning, structural analysis and
functional expression of the proline-rich focal adhesion and
microfilament-associated protein VASP. EMBO J. 14:19–27. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pula G and Krause M: Role of Ena/VASP
proteins in homeostasis and disease. Handb Exp Pharmacol. 39–65.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen XJ, Squarr AJ, Stephan R, Chen B,
Higgins TE, Barry DJ, Martin MC, Rosen MK, Bogdan S and Way M:
Ena/VASP proteins cooperate with the WAVE complex to regulate the
actin cytoskeleton. Dev Cell. 30:569–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Han G, Fan B, Zhou Y, Zhou X, Wei
L and Zhang J: Green tea (−)-epigallocatechin-3-gallate
down-regulates VASP expression and inhibits breast cancer cell
migration and invasion by attenuating Rac1 activity. Eur J
Pharmacol. 606:172–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galler AB, García Arguinzonis MI,
Baumgartner W, Kuhn M, Smolenski A, Simm A and Reinhard M:
VASP-dependent regulation of actin cytoskeleton rigidity, cell
adhesion, and detachment. Histochem Cell Biol. 125:457–474. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knauer O, Binai NA, Carra G, Beckhaus T,
Hanschmann KM, Renné T, Backert S, Karas M and Wessler S:
Differential phosphoproteome profiling reveals a functional role
for VASP in Helicobacter pylori-induced cytoskeleton
turnover in gastric epithelial cells. Cell Microbiol. 10:2285–2296.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu K, Li L, Nisson PE, Gruber C, Jessee J
and Cohen SN: Reversible tumorigenesis induced by deficiency of
vasodilator-stimulated phosphoprotein. Mol Cell Biol. 19:3696–3703.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su K, Hu P, Wang X, Kuang C, Xiang Q, Yang
F, Xiang J, Zhu S, Wei L and Zhang J: Tumor suppressor berberine
binds VASP to inhibit cell migration in basal-like breast cancer.
Oncotarget. 7:45849–45862. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su K, Tian Y, Wang J, Shi W, Luo D, Liu J,
Tong Z, Wu J, Zhang J and Wei L: HIF-1α acts downstream
of TNF-α to inhibit vasodilator-stimulated
phosphoprotein expression and modulates the adhesion and
proliferation of breast cancer cells. DNA Cell Biol. 31:1078–1087.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Y, Hu PC, Gao FF, Lv JW, Xu S, Kuang
CC, Wei L and Zhang JW: The protective effect of curcumin on
hepatotoxicity and ultrastructural damage induced by cisplatin.
Ultrastruct Pathol. 38:358–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dertsiz L, Ozbilim G, Kayisli Y, Gokhan
GA, Demircan A and Kayisli UA: Differential expression of VASP in
normal lung tissue and lung adenocarcinomas. Thorax. 60:576–581.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gyorffy B, Surowiak P, Budczies J and
Lanczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X and Adjei AA: Lung cancer and
metastasis: New opportunities and challenges. Cancer Metastasis
Rev. 34:169–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baxevanis CN, Voutsas IF, Tsitsilonis OE,
Tsiatas ML, Gritzapis AD and Papamichail M: Compromised anti-tumor
responses in tumor necrosis factor-alpha knockout mice. Eur J
Immunol. 30:1957–1966. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Prevost-Blondel A, Roth E, Rosenthal FM
and Pircher H: Crucial role of TNF-alpha in CD8 T cell-mediated
elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J
Immunol. 164:3645–3651. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tandle A, Hanna E, Lorang D, Hajitou A,
Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S and
Libutti SK: Tumor vasculature-targeted delivery of tumor necrosis
factor-alpha. Cancer. 115:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang J, Zhang J, Wu J, Luo D, Su K, Shi W,
Liu J, Tian Y and Wei L: MicroRNA-610 inhibits the migration and
invasion of gastric cancer cells by suppressing the expression of
vasodilator-stimulated phosphoprotein. Eur J Cancer. 48:1904–1913.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Henes J, Schmit MA, Morote-Garcia JC,
Mirakaj V, Köhler D, Glover L, Eldh T, Walter U, Karhausen J,
Colgan SP and Rosenberger P: Inflammation-associated repression of
vasodilator-stimulated phosphoprotein (VASP) reduces
alveolar-capillary barrier function during acute lung injury. FASEB
J. 23:4244–4255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azoitei N, Becher A, Steinestel K, Rouhi
A, Diepold K, Genze F, Simmet T and Seufferlein T: PKM2 promotes
tumor angiogenesis by regulating HIF-1α through NF-κB
activation. Mol Cancer. 15:32016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carmeliet P, Dor Y, Herbert JM, Fukumura
D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R,
Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis,
cell proliferation and tumour angiogenesis. Nature. 394:485–490.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Haddad JJ and Harb HL: Cytokines and the
regulation of hypoxia-inducible factor (HIF)-1alpha. Int
Immunopharmacol. 5:461–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Wong CC, Wei H, Gilkes DM,
Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B,
Winnard PT Jr, et al: HIF-1-dependent expression of
angiopoietin-like 4 and L1CAM mediates vascular metastasis of
hypoxic breast cancer cells to the lungs. Oncogene. 31:1757–1770.
2012. View Article : Google Scholar : PubMed/NCBI
|
